This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teleflex (TFX) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 2.33% and 0.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Teleflex (TFX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Teleflex (TFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights Comcast, Aon, Trane Technologies, Huntington Bancshares and Teleflex
by Zacks Equity Research
Comcast, Aon, Trane Technologies, Huntington Bancshares and Teleflex are part of the Zacks top Analyst Blog.
Top Analyst Reports for Comcast, Aon & Trane Technologies
by Santanu Roy
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Aon plc (AON) and Trane Technologies plc (TT).
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.
Teleflex (TFX) OEM Arm Grows, Supply Issue Persists
by Zacks Equity Research
From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.
Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut
by Zacks Equity Research
For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.
Teleflex (TFX) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 5.48% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Teleflex (TFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tactile Systems Technology (TCMD) Moves 6.6% Higher: Will This Strength Last?
by Zacks Equity Research
Tactile Systems Technology (TCMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teleflex (TFX) Witnesses Lower UroLift Sales, Cost Woes
by Zacks Equity Research
Teleflex's (TFX) lowered revenue and adjusted EPS outlook for 2022 indicates lackluster performance, which increases investors' concern.
Teleflex (TFX) Hit by Urolift Volume Decline, Cost Pressure
by Zacks Equity Research
In the Americas, growth within the Surgical business of Teleflex (TFX) is offset by a decline in Interventional Urology.
Teleflex's (TFX) Q2 Earnings Top Estimates, 2022 View Down
by Zacks Equity Research
For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.
Teleflex (TFX) Q2 Earnings Beat Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 1.19% and 2.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.
Why Is Globus Medical (GMED) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Idexx (IDXX) Up 0.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) Q1 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.
Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.
QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.